We are live on ! Find out more
RPRX icon

Royalty Pharma
RPRX

378 hedge funds and large institutions have $8.35B invested in Royalty Pharma in 2024 Q2 according to their latest regulatory filings, with 60 funds opening new positions, 141 increasing their positions, 127 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

222% more call options, than puts

Call options by funds: $13.5M | Put options by funds: $4.19M

11% more repeat investments, than reductions

Existing positions increased: 141 | Existing positions reduced: 127

1.94% more ownership

Funds ownership: 68.15% → 70.09% (+1.9%)

7% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 56

0% more funds holding

Funds holding: 378 → 378 (0)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

10% less capital invested

Capital invested by funds: $9.24B → $8.35B (-$885M)

Holders
378
Holders Change
–
Holders Change %
0%
% of All Funds
5.46%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
60
Increased
141
Reduced
127
Closed
56
Calls
$13.5M
Puts
$4.19M
Net Calls
+$9.31M
Net Calls Change
+$4.69M

Top Buyers

1
Swedbank
Swedbank
Sweden
+$300M
2
BlackRock
BlackRock
New York
+$50.2M
3
BGIM
Brandywine Global Investment Management
Pennsylvania
+$45.4M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$29.5M
5
Invesco
Invesco
Georgia
+$29.5M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$159M
2
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$81.4M
3
Millennium Management
Millennium Management
New York
-$64.2M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$15.8M
5
CSS
Cubist Systematic Strategies
Connecticut
-$14.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
PPW
251
PACK Private Wealth
Minnesota
$459K – – –
CLOS
252
Compagnie Lombard Odier SCmA
Switzerland
$448K – – –
SACTSONJ
253
Supplemental Annuity Collective Trust (SACT) of New Jersey
New Jersey
$448K – – –
SPA
254
Sherbrooke Park Advisers
New York
$447K +$470K +16,968 New
MGP
255
M&G plc
United Kingdom
$447K +$477K +17,200 New
PA
256
Profund Advisors
Maryland
$443K -$89.8K -3,238 -16%
SOMRS
257
State of Michigan Retirement System
Michigan
$440K +$133K +4,800 +40%
SAM
258
Sectoral Asset Management
Quebec, Canada
$439K -$76.8K -2,770 -14%
FFM
259
Fullerton Fund Management
Singapore
$422K +$444K +16,002 New
HHGC
260
Hunting Hill Global Capital
New York
$420K – – –
Rockefeller Capital Management
261
Rockefeller Capital Management
New York
$419K -$114K -4,129 -21%
CM
262
Capula Management
Cayman Islands
$408K +$429K +15,470 New
ECP
263
Epacria Capital Partners
Colorado
$400K +$420K +15,164 New
Rafferty Asset Management
264
Rafferty Asset Management
New York
$395K -$47.7K -1,722 -10%
Aviva
265
Aviva
United Kingdom
$374K – – –
AAS
266
Avantax Advisory Services
Texas
$372K +$391K +14,089 New
SSA
267
Schonfeld Strategic Advisors
New York
$371K +$85K +3,065 +28%
Truist Financial
268
Truist Financial
North Carolina
$356K -$283K -10,211 -43%
RFC
269
Regions Financial Corp
Alabama
$345K +$85.9K +3,100 +31%
IIM
270
Ironwood Investment Management
Massachusetts
$343K – – –
AFCM
271
Applied Finance Capital Management
Puerto Rico
$340K +$357K +12,892 New
IIM
272
INTECH Investment Management
Florida
$335K – – –
MYAM
273
Meiji Yasuda Asset Management
Japan
$315K – – –
DTL
274
Dynamic Technology Lab
Singapore
$315K -$437K -15,768 -57%
RJT
275
Raymond James Trust
Florida
$314K -$748 -27 -0.2%
9 10
11
12 13

RPRX Hedge Fund Activity: Q2 2024 in Review

378 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q2 2024, worth a combined $8.35B — down 9.6% from $9.24B a quarter earlier.

Buyers outnumbered sellers: 60 funds opened new RPRX positions and 56 closed out — a net gain of 4 holders — while 141 added to existing stakes and 127 trimmed.

The largest buyer was Swedbank, opening a new position worth an estimated $300M. The largest seller was Fidelity Investments, cutting an estimated $159M.

  • 378 institutional investors held Royalty Pharma (RPRX) as of Q2 2024, unchanged from Q1 2024.
  • Funds reported $8.35B of Royalty Pharma stock for Q2 2024, down 9.6% quarter-over-quarter.
  • 60 funds opened new Royalty Pharma positions in Q2 2024 and 56 closed out, a net change of +4 holders.
  • The largest Royalty Pharma buyer in Q2 2024 was Swedbank, an estimated $300M added.
  • The largest Royalty Pharma seller in Q2 2024 was Fidelity Investments, an estimated $159M sold.

Based on aggregated 13F filings for Q2 2024.